Current work by our group using mutant KRAS and TP53 (KP) mouse models of NSCLC have shown that rationally designed therapies combining PD-L1 immune checkpoint blockade with MEK inhibitors significantly decrease tumor growth and metastasis compared to either monotherapies in syngeneic KP mice tumors. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.